REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial ...Middle East

First patient received dose level 2 of RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin On track for pivotal dose determination and initiation of pivotal program in 2024 ROCKVILLE, Md., Nov. 29,...

Hence then, the article about regenxbio announces dose escalation in affinity duchenne trial was published today ( Wednesday 29/11/2023 - 03:13 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial )

Also on site :

• I went to Cambridge from state school and was patronised and laughed at
• Pricer launches commercially ready Pricer Avenue™ at NRF, redefining the shelf edge for high-value retail zones
• High Wind Warning issued January 11 at 12:39AM PST until January 11 at 1:00PM PST by NWS Los Angeles/Oxnard CA